Eupraxia Pharmaceuticals (EPRX) Cash from Financing Activities (2023 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Cash from Financing Activities of $68.6 million for Q1 2026, up 15852.39% year-over-year from N/an in Q1 2025, and up 4499.97% quarter-over-quarter from $1.5 million in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Cash from Financing Activities (2023 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Cash from Financing Activities for 4 consecutive years, with $68.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 15852.39% year-over-year to $68.6 million; the TTM figure through Mar 2026 stood at $144.2 million (up 525.81% YoY), while the FY2025 annual figure was $76.1 million, up 66.12% from the prior year.
- Cash from Financing Activities improved to $68.6 million in Q1 2026 per EPRX's latest filing, from $1.5 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $73.9 million in Q3 2025 and bottomed at -$4.6 million in Q3 2024.
- Historically, Cash from Financing Activities has averaged $16.3 million across 4 years, with a median of $1.5 million in 2025.
- On a YoY basis, Cash from Financing Activities climbed as much as 532658.26% in 2024 and fell as far as 198.36% in 2024.
- Eupraxia Pharmaceuticals' Cash from Financing Activities stood at $5956.0 in 2023, then soared by 532658.26% to $31.7 million in 2024, then slumped by 95.3% to $1.5 million in 2025, then jumped by 4499.97% to $68.6 million in 2026.
- Business Quant data shows EPRX's Cash from Financing Activities at $68.6 million in Q1 2026, $1.5 million in Q4 2025, and $73.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Eupraxia Pharmaceuticals | 381.11 Mn | 379.51 Mn | - | 68.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68.58 Mn |
| Mar 31, 2026 | 68.58 Mn |
| Dec 31, 2025 | 1.49 Mn |
| Dec 31, 2025 | 1.49 Mn |
| Sep 30, 2025 | 73.90 Mn |
| Sep 30, 2025 | 73.90 Mn |
| Jun 30, 2025 | 239,778.00 |
| Jun 30, 2025 | 239,778.00 |
| Mar 31, 2025 | 429,923.00 |
| Mar 31, 2025 | 429,923.00 |
| Dec 31, 2024 | 31.73 Mn |
| Dec 31, 2024 | 31.73 Mn |
| Sep 30, 2024 | -4.60 Mn |
| Sep 30, 2024 | -4.60 Mn |
| Jun 30, 2024 | -4.52 Mn |
| Jun 30, 2024 | -4.52 Mn |
| Mar 31, 2024 | 23.17 Mn |
| Mar 31, 2024 | 23.17 Mn |
| Dec 31, 2023 | 5,956.00 |
| Dec 31, 2023 | 5,956.00 |